Aarti Pharmalabs Limited share price
NSE: AARTIPHARM · ISIN INE0LRU01027
Key numbers
- Market cap
- ₹ 8,520 Cr
- Current price
- ₹ 939.55
- 52-week high / low
- ₹ 962 / 585
- Stock P/E
- 41.9
- Book value
- ₹ 234.3
- Dividend yield
- 0.43%
- ROCE
- 10.5%
- ROE
- 8.5%
- Debt to equity
- 0.36
- Sales growth (3 yrs)
- -2.6%
- Profit growth (3 yrs)
- -3.3%
- 1-year return
- 9.6%
About Aarti Pharmalabs Limited
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, ophthalmologic, antidepressant medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates, such as xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. It serves pharmaceutical, nutraceutical, and beverage industries. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 386 | 418 | 432 | 583 | 536 |
| Operating profit | 95 | 75 | 102 | 130 | 133 |
| Net profit | 46 | 28 | 48 | 61 | 76 |
| EPS (₹) | 5.08 | 3.08 | 5.29 | 6.74 | 8.40 |
Investor presentation summary (2026-08-10)
AI summary of the presentation · tone: Positive · source document
Key numbers
- Expanded capacity is expected to drive global market share from 15–20% to 20–25%.
- EBITDA Margin (%) 24.82% 23.13% 169 Bps 25.34% (52) Bps
Guidance & outlook
- Please find enclosed herewith the Q1 FY27 Results Presentation of the Company for your
- group turnover of INR 145+ bn (FY26)
Growth & demand
- Acquired land at Atali for future growth
- Specialized player in the development and manufacturing of HPAPIs, catering to the demand for
Margins & costs
- Finance costs 129 169 (23.7)% 68 89.7%
- PAT Margin (%) 14.20% 10.49% 371 Bps 11.91% 229 Bps
Capex & expansion
- Commissioned Caffeine production at Unit 5 with a capacity of 100
- Commissioned Phase 1 at Atali greenfield site
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.